Ogeda S.A.

19 patents currently held · Updated Nov 14, 2026

11 more in force are now held by other companies

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

Jun 2027

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Jul 28, 2027
The maintenance fee for NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders (US 10,544,150) comes due Jul 28, 2027. Unpaid by Jan 28, 2028, it lapses early.
1 fee due Oct 21, 2027
The maintenance fee for NK-3 Receptor Antagonists for Therapeutic or Cosmetic Treatment of Excess Body Fat (US 10,624,890) comes due Oct 21, 2027. Unpaid by Apr 21, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

1 term has ended since Aug 16, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Patent	Title	Status	Expires	Confidence
US 7,824,866	Ligand for G-protein coupled receptor GPR72 and uses thereof In force Term ends Jun 12, 2027 · From the USPTO record	In force	Term ends Jun 12, 2027	From the USPTO record
US 8,871,761	NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders In force Term ends Apr 4, 2031 · From the USPTO record	In force	Term ends Apr 4, 2031	From the USPTO record
US 9,926,325	NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders In force Ends no later than Apr 4, 2031 · From the USPTO record	In force	Ends no later than Apr 4, 2031	From the USPTO record
US 10,065,960	NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders In force Ends no later than Apr 4, 2031 · From the USPTO record	In force	Ends no later than Apr 4, 2031	From the USPTO record
US 10,544,150	NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders In force Ends no later than Apr 4, 2031 · From the USPTO record	In force	Ends no later than Apr 4, 2031	From the USPTO record
US 9,475,814	Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof In force Ends no later than Oct 3, 2032 · From the USPTO record	In force	Ends no later than Oct 3, 2032	From the USPTO record
US 10,065,961	Chiral N-acyl-5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof In force Term ends Oct 3, 2032 · From the USPTO record	In force	Term ends Oct 3, 2032	From the USPTO record
US 10,683,295	Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-A]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof In force Term ends Oct 3, 2032 · From the USPTO record	In force	Term ends Oct 3, 2032	From the USPTO record
US 10,941,151	Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof In force Term ends Oct 3, 2032 · From the USPTO record	In force	Term ends Oct 3, 2032	From the USPTO record
US 9,840,508	N-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a] pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders In force Term ends Mar 28, 2034 · From the USPTO record	In force	Term ends Mar 28, 2034	From the USPTO record

10 of 19 patents shown.

Pro members see all 19.

Pro members: see all 19 patents

Also on record, not counted in the 19: 11 patents in force now held by others · 28 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

3 no status recorded

List them